Korean companies urged to seek M&As to counter drug price cuts and US FTA

Domestic drug makers should focus on seeking mergers & acquisitions (M&As) to enlarge their sales volume to survive in an era of the Korea-U.S. FTA and massive drug price cuts, an expert said.

“Local companies should seek a feasible method to maximize the synergistic effects through M&A among themselves as they can no longer expect success only by depending on making generic drugs,” said Dr....